NASDAQ:ODT - Odonate Therapeutics Stock Price, Price Target & More

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics Inc (NASDAQ:ODT) posted its earnings results on Thursday, May, 3rd. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.16. View Odonate Therapeutics' Earnings History.

3 equities research analysts have issued twelve-month price targets for Odonate Therapeutics' shares. Their forecasts range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' share price to reach $33.50 in the next twelve months. View Analyst Ratings for Odonate Therapeutics.

Some companies that are related to Odonate Therapeutics include Emergent Biosolutions (EBS), Evotec (EVTCY), TESARO (TSRO), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Clovis Oncology (CLVS), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Endo International (ENDP), Insmed (INSM), Spectrum Pharmaceuticals (SPPI) and Prestige Brands (PBH).

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics' lock-up period expired on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its IPO on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Press coverage about ODT stock has trended somewhat negative recently, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Odonate Therapeutics earned a news sentiment score of -0.04 on Accern's scale. They also gave headlines about the company an impact score of 48.87 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Odonate Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (46.16%), Sabby Management LLC (2.73%), Redmile Group LLC (2.21%), Rock Springs Capital Management LP (1.43%), BlackRock Inc. (1.06%) and Victory Capital Management Inc. (0.30%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.

ODT stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC, Rock Springs Capital Management LP, Victory Capital Management Inc. and Redmile Group LLC. View Insider Buying and Selling for Odonate Therapeutics.

ODT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Tang Capital Management LLC, Northern Trust Corp, Schwab Charles Investment Management Inc., California State Teachers Retirement System and The Manufacturers Life Insurance Company . Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $24.98.

Odonate Therapeutics has a market capitalization of $667.36 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]